Hypercholesterolemia: Clinical Trials

22 trials for Hypercholesterolemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

22 terminated. 22 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 322Terminated 22

Follow Hypercholesterolemia: new trials by email Literature Review of Hypercholesterolemia trials Research Report on Hypercholesterolemia

Trials (filtered) newest first · largest first

All 22 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Efficacy of Evolocumab in Addition to Optimal Stable Background Statin Therapy in Chinese Participants With Primary Hypercholesterolemia and Mixed Dyslipidemia
evolocumab, placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedAmgen2592019-05-092023-03-27
A Study of Evacetrapib (LY2484595) in Combination With Atorvastatin in Japanese Participants With Primary Hypercholesterolemia
Evacetrapib, Ezetimibe, Atorvastatin - Hypercholesterolemia
Phase 3TerminatedEli Lilly and Company1492015-01-012018-10-09
A Study of Evacetrapib (LY2484595) in Japanese Participants With Primary Hypercholesterolemia
Evacetrapib, Placebo - Hypercholesterolemia
Phase 3TerminatedEli Lilly and Company542014-11-012018-10-09
Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Placebo, Eprotirome - Heterozygous Familial Hypercholesterolaemia
Phase 3TerminatedKaro Bio AB2362011-10-012012-09-03
Efficacy and Safety of Extended-Release Niacin/ Laropiprant/Simvastatin Tablets in Participants With Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-143)
ER niacin/laropiprant (ERN/LRPT), ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM), Simvastatin (SIM) - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC11392011-05-012019-02-06
Effects of a Supplement Derived From Palm Oil on Cholesterol Levels in the Blood
Gamma Delta Tocotrienols - Low Dose, Gamma Delta Tocotrienols - High Dose, Sugar Pill - Hypercholesterolemia
Phase 3TerminatedUniversity of California, Los Angeles132011-03-222019-02-12
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
Extended-release niacin/laropiprant (ERN/LRPT), Placebo - Primary Hypercholesterolemia, Mixed Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC11732011-03-012024-05-22
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT) - Primary Hypercholesterolemia, Dyslipidemia
Phase 3TerminatedMerck Sharp & Dohme LLC9772011-02-042018-08-16
Ezetimibe in Patients Hypo-responsive to Statins
Ezetimibe, Atorvastatin - High Cholesterol, Coronary Artery Disease
Phase 3TerminatedUniversity of California, San Diego22009-09-012019-08-21
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia
AVE5530, Placebo - Hypercholesterolemia
Phase 3TerminatedSanofi6432008-10-012016-05-16
Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia
AVE5530, atorvastatin, placebo - Hypercholesterolemia
Phase 3TerminatedSanofi17362008-08-012016-05-16
Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia
25 mg/day AVE5530, 50 mg/day AVE5530, placebo - Hypercholesterolemia
Phase 3TerminatedSanofi10152008-07-012016-05-16
Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia
AVE5530, Placebo - Hypercholesterolemia
Phase 3TerminatedSanofi8262008-07-012016-05-16
Efficacy of Lapaquistat Acetate on Blood Cholesterol Levels in Treating Subjects With Hypercholesterolemia
Lapaquistat acetate, Placebo - Hypercholesterolemia
Phase 3TerminatedTakeda6572007-10-012012-05-24
INdians Followed for INtensive Lipid Lowering Treatment and Its safetY
ezetimibe, Comparator: Simvastatin 20, 40 and 80 mg, Comparator: Atorvastatin - Hypercholesterolemia
Phase 3TerminatedSunnybrook Health Sciences Centre642007-08-012011-07-28
Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia
Lapaquistat acetate and stable statin therapy, Stable statin therapy - Hypercholesterolemia
Phase 3TerminatedTakeda4112007-07-012016-06-22
Evaluation of Atorvastatin Treatment on Carotid Plaque.
Atorvastatin - Cardiovascular Diseases
Phase 3TerminatedPfizer's Upjohn has merged with Mylan to form Viatris Inc.1602007-01-012021-02-18
A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).
torcetrapib/atorvastatin, simvastatin - Hyperlipidemia, Dyslipidemia
Phase 3TerminatedPfizer6402006-01-012012-02-17
Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia
Lapaquistat acetate and stable statin therapy, Stable statin therapy - Hypercholesterolemia
Phase 3TerminatedTakeda6492005-11-012012-05-24
Efficacy of Lapaquistat Acetate Co-Administered With Current Lipid-Lowering Treatment on Blood Cholesterol Levels in Subjects With Homozygous Familial Hypercholesterolemia
Lapaquistat acetate and current lipid-lowering treatment, Current lipid-lowering treatment - Hypercholesterolemia
Phase 3TerminatedTakeda442005-11-012012-05-24

Showing 20 of 22. Sign in to see all of them.

Narrower conditions

Dyslipidemias (5)  ·  Hyperlipidemias (5)  ·  Coronary Artery Disease (2)  ·  Atherosclerosis (1)  ·  Cardiovascular Diseases (1)  ·  Thyroid Diseases (1)

Broader conditions

Lipid Metabolism Disorders (22)  ·  Metabolic Diseases (22)  ·  Nutritional and Metabolic Diseases (22)  ·  Dyslipidemias (17)  ·  Hyperlipidemias (17)  ·  Arterial Occlusive Diseases (3)  ·  Arteriosclerosis (3)  ·  Cardiovascular Diseases (3)  ·  Vascular Diseases (3)  ·  Coronary Disease (2)  ·  Heart Diseases (2)  ·  Myocardial Ischemia (2)  ·  Endocrine System Diseases (1)

Interventions

Atorvastatin (7)  ·  Simvastatin (6)  ·  1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (4)  ·  Ezetimibe (4)  ·  MK-0524 (3)  ·  Rosuvastatin Calcium (2)  ·  evacetrapib (2)  ·  3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid (1)  ·  Ezetimibe, Simvastatin Drug Combination (1)  ·  Fluvastatin (1)  ·  Lovastatin (1)  ·  Niacin (1)  ·  Pravastatin (1)  ·  Sugars (1)  ·  evolocumab (1)

Sponsors

Sanofi (4)  ·  Takeda (4)  ·  Merck Sharp & Dohme LLC (3)  ·  Eli Lilly and Company (2)  ·  Amgen (1)  ·  Drug Commission of the German Medical Association (1)  ·  Karo Bio AB (1)  ·  Organon and Co (1)  ·  Pfizer (1)  ·  Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (1)  ·  Sunnybrook Health Sciences Centre (1)  ·  University of California, Los Angeles (1)  ·  University of California, San Diego (1)

Countries

United States (11)  ·  Canada (5)  ·  Israel (4)  ·  France (3)  ·  Netherlands (3)  ·  Russia (3)  ·  Australia (2)  ·  Belgium (2)  ·  Czechia (2)  ·  Hungary (2)  ·  Japan (2)  ·  Norway (2)  ·  Poland (2)  ·  Puerto Rico (2)  ·  Slovakia (2)

Top investigators

David Heber, MD, PhD (1)  ·  Davidson Michael, MD (1)  ·  Heiner K. Berthold, MD, PhD (1)  ·  John Kastelein, Professor (1)  ·  Ori Ben-Yehuda, MD (1)  ·  Zhaoping Li, MD, PhD (1)

Results publications

PMID 21518985, PMID 16705107, PMID 24731671

NIH funding

2005 (2)